The market is changing fast. Stay up to date here. Forget the outdated PDFs no one finishes and the charts that don’t say anything. We've made everything fresh, clear, and straightforward.
The femtech market report covers 12 topics
Before we start, we make the market super clear ... what’s in, what’s out, the main segments, and what’s "next to it" but not included.
We do this because people often mean different things when they talk about this market.
It helps you interpret the data the right way.
In 2026, we can say that femtech looks past the hype-cycle peak. However, the market is still hot.
We have identified strong signals. Allara’s $26M Series B, Midi Health’s $50M Series C or FDA label expansion for Addyi are some of them.
In this section, we will see why now is a good time to build and invest in this market.
There are tons of femtech market size and CAGR numbers online, and they’re all over the place. It’s tough to know what to trust.
This deck gives you a clear, defensible estimate. We start with first-principles analysis, verify it with aggregated sources, and document every assumption. We also show the reasoning behind the result so you can pressure-test it yourself.
The point is to give you numbers you can trust ... and a fast sanity check on whether this market is worth pursuing.
There are widespread problems in women's health. Patients, OB-GYNs, employers, and insurers all deal with gaps that femtech products and services can fill.
We show you who the customers are and what issues they're trying to solve.
Understanding these pain points lets you build or back solutions that people actually need and will pay for.
Fertility trackers, menopause solutions, pelvic health devices, hormone monitoring platforms: the femtech market is expanding fast, and new players keep entering the space.
That's why we keep this section current with what's launched, what's in trials, and what's being built. Diagnostic tools, personalized care apps, and the infrastructure supporting women's health at every stage.
A refreshed view of a market finally getting the attention it deserves.
DTC subscriptions, telehealth visits, employer benefits, payer reimbursement, device sales, and clinic partnerships are just a few of the ways femtech companies make money.
We show which business models are working right now, and why certain segments deliver 10x better unit economics than others.
You’ll understand who pays, when, and for what ... so you don’t build or invest in something meaningful that people won’t actually adopt (or pay for).
There are the risks you’ve heard of and everyone knows in femtech: reimbursement friction, strict clinical standards, and distribution challenges, among other factors.
But there are other things to keep in mind, like privacy sensitivity, stigma that affects retention, and stricter scrutiny of marketing claims.
In this section, we map the challenges and how likely they are, so you can plan ahead before you invest or build.
Growth rate numbers do not mean anything for the femtech market if you do not understand what drives trust, clinical adoption, and repeat use.
Some drivers are easy to see: more openness around women’s health, demand for personalized care, and growing innovation. But scale often depends on less obvious enablers like clinical validation, privacy and data stewardship, integration into care pathways, and reimbursement or employer benefits that reduce friction.
Before building or investing, you should know what needs to happen for the market growth to accelerate.
A lot of investors love the femtech market because it’s an overlooked set of problems with real demand, and the best products earn trust and stick around. In this section, we’ll show you where money is flowing and what’s actually getting funded right now.
You’ll see which companies are raising, plus what those rounds have in common: the care pathways and product angles investors keep leaning into, what they’re excited about today, and what they’ve mostly stopped backing.
We’ll also flag the newer theses starting to gain traction.
Flo and Maven Clinic may be household names in women's health, but the femtech market is expanding fast beyond period tracking and fertility.
Startups are addressing menopause, pelvic health, hormonal conditions, maternal care, and diseases historically overlooked by mainstream medicine.
In our conversations with entrepreneurs and investors, we've found confusion at every turn: around reimbursement pathways, regulatory hurdles, and how to reach consumers at scale. That's why we built this section for them.
Below, you'll find the market grids and ecosystem maps we've created to bring clarity to what's emerging and where the biggest opportunities lie.
The femtech market isn’t a guaranteed goldmine. It’s a trust-heavy space: evidence matters, regulation can bite, and distribution often runs through clinicians, employers, or platforms.
So we studied femtech startups that failed and pulled out the non-obvious patterns: the quiet traps you don’t see in generic startup advice, like weak validation, fuzzy reimbursement, or products that don’t match real user behavior.
This way, if you’re building, you start ahead. If you’re investing, you can spot the red flags much earlier.
Flo, Clue, Maven Clinic, Natural Cycles… femtech has its share of category winners.
What did they do differently in a space that demands both empathy and rigor? The leaders win by earning trust, designing for long-term habits, and pairing great UX with medical/clinical credibility where it matters.
We analyzed the femtech leaders’ strongest moves, and this section shares the cheat codes you can apply right away.
Founders, investors, operators, and strategists exploring or already active in the market.
Weeks of fragmented research and conflicting data, condensed into one coherent view.
We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women’s biology, care pathways, or life stages.
Yes. All key data points and assumptions are explained and sourced in the deck.
All sources are tier-1: company filings, funding databases, public datasets, expert interviews, industry reports, etc.
Yes. The deck was last updated on March 3, 2026 with the latest market signals.
Yes. No subscription or hidden fees.
Yes. You can use NEWMARKET for 20% off when purchasing two reports, or NEWMARKETMAX for 30% off when purchasing five or more.
If a market you care about is not currently on the list, email us at team@newmarketpitch.com and we may be able to cover it.
No problem. You can reach out directly and we respond within 24 hours.
Whether you're starting a company, investing, or researching competitors, making decisions with bad data is expensive. This report provide the latest verified insights, visualized clearly so you can move faster and minimize costly mistakes.
